Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern
Gururaj Deshpande, Pragya D. Yadav, Priya Abraham, Dimpal A. Nyayanit, Gajanan Sapkal, Anita M. Shete, Nivedita Gupta, Krishna Mohan Vadrevu, Raches Ella, Samiran Panda, Balram Bhargava
Abstract
The neutralizing antibody responses were significantly elevated after 3rd dose of BBV152/Covaxin against the B.1 (19.11 fold) variant including Delta (16.51 fold), Beta (14.70 fold) and Omicron (18.53 fold) Variants of concern in comparison with two dose vaccine, providing assurance of a protective immune response of booster in recipients.
Topics & Concepts
MedicineNeutralizing antibodyVirologyBooster doseAntibody responseCoronavirus disease 2019 (COVID-19)AntibodyBooster (rocketry)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BETA (programming language)ImmunologyTiterInternal medicineInfectious disease (medical specialty)Programming languagePhysicsComputer scienceAstronomyDiseaseSARS-CoV-2 and COVID-19 ResearchInfluenza Virus Research StudiesCOVID-19 Clinical Research Studies